Business
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utilityKELOWNA, BC / ACCESSWIRE / May 23, 2023 / Lexaria Bioscience
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utilityKELOWNA, BC / ACCESSWIRE / May 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms is pleased to announce additional findings from last year's human clinical study HYPER-H21-4 (\"the Study\") demonstrating significant reductions in several pro-inflammatory biomarkers known to be linked to cardiovascular disease (\"CVD\") and a host of other conditions.After five weeks of treatment with the patented DehydraTECH-processed cannabidiol (\"CBD\") capsule formulation, blood-plasma levels of interleukin (\"IL\") 8, 10, and 18 were reduced by ~19%, ~27%, and ~43%, respectively. Those persons receiving five weeks of placebo experienced no significant changes in their IL levels as shown with the black bars in the graph below. The differences evidenced relative to baseline and/or placebo with pro-inflammatory biomarkers IL 8, 10 and 18 were statistically significant (p","length":1239,"tagName":"div"}]